New drug duo tested for Tough-to-Treat bone cancer

NCT ID NCT07479732

Summary

This study is testing a combination of two drugs, apatinib and liposomal irinotecan, for people with advanced osteosarcoma (a type of bone cancer) that has come back or spread after standard chemotherapy. The main goals are to find the safest and most effective dose of the two drugs together and to see how well they work at controlling the cancer. It is for patients whose cancer has progressed after at least two prior lines of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.